Direct Stock Purchases vs Cannabis ETF Investing: Which Is Better for Cannabis Investors?

This comparison focuses specifically on the practical mechanics, costs, and outcomes of the two primary methods for gaining cannabis sector exposure. While related to the broader stocks-vs-ETFs question, this analysis emphasizes the operational and structural differences that affect real-world returns.

Direct stock purchasing gives you precise control over your cannabis exposure. You decide exactly which companies to own and in what proportions. If you believe Trulieve is the best-run MSO, you can allocate 30% of your cannabis portfolio to it — something an ETF will never do (MSOS caps individual positions at approximately 10-15%). This concentration can dramatically amplify returns when you are right, as owning the top-performing cannabis stock directly yields its full return rather than its diluted contribution to a diversified basket.

The cost structure of direct stock ownership is unambiguously better for buy-and-hold investors. Once you purchase shares, there are no ongoing fees — zero expense ratio, zero management fee, zero administrative charges. Compare this to MSOS at 0.75% annual expense ratio or MJ at 0.75%. On a $50,000 cannabis portfolio held for 10 years, the ETF wrapper would cost approximately $3,750 in fees (simplified calculation, actual depends on portfolio value changes). For active traders, the cost difference is minimal since trading commissions are now zero at most brokers.

However, direct ownership imposes significant time costs and knowledge requirements. To build a properly diversified cannabis portfolio, you need to research and monitor 8-15 individual companies. This means reading quarterly earnings releases, tracking state-level regulatory changes, monitoring share dilution, and rebalancing positions as market caps shift. Cannabis is a fast-moving sector where material news can break at any time — a company you own might announce a stock dilution at 4:01 PM that you do not see until the next morning, when the stock has already gapped down 15%.

ETFs handle all of this automatically. Professional portfolio managers research companies, the fund rebalances according to its methodology, and new companies are added while underperformers are removed without any action required from you. For investors who want cannabis exposure as part of a broader portfolio but do not want to become cannabis industry experts, ETFs are the practical solution. The 0.75% annual fee is the price of delegation — and for most investors it is well worth paying.

Tax considerations add nuance. Direct stock ownership allows tax-loss harvesting at the individual security level — you can sell a losing position to realize a capital loss while maintaining overall cannabis exposure through other holdings. ETFs provide less tax-loss harvesting flexibility because selling the ETF means exiting your entire cannabis position. On the other hand, ETFs benefit from in-kind creation/redemption mechanisms that can defer capital gains. The net tax impact depends on your specific situation and trading patterns.

One unique consideration for cannabis: the MSOS ETF uses swap agreements to gain exposure to OTC-traded MSOs, since the fund itself trades on a major exchange. This swap structure introduces counterparty risk and tracking error that direct stock ownership avoids. If the swap counterparty faces difficulties, the ETF's performance could deviate from the underlying stocks. This is a structural risk specific to cannabis ETFs that does not exist in most other sector ETFs.